Financial Performance - The company's revenue for Q1 2022 reached ¥1,442,770,395.49, representing a 165.77% increase compared to ¥542,859,651.10 in the same period last year[4] - Net profit attributable to shareholders was ¥381,898,709.67, a significant increase of 333.53% from ¥88,091,336.52 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥381,009,392.25, up 406.20% from ¥75,267,992.56 in the previous year[4] - Basic and diluted earnings per share were both ¥0.70, reflecting a 337.50% increase from ¥0.16 in the previous year[4] - The total comprehensive income attributable to the parent company reached CNY 397,671,079.70, a significant increase from CNY 85,943,396.25 in the previous year[36] Cash Flow - The net cash flow from operating activities was ¥334,267,821.88, showing an impressive increase of 839.13% compared to ¥35,593,516.02 in the same quarter last year[4] - Cash received from sales and services amounted to ¥1,270,444,901.92, up 185.53% from ¥444,939,528.14 in the same period last year[11] - Cash inflow from financing activities was CNY 589,756,133.95, significantly higher than CNY 35,593,856.49 in the same period last year[40] - The net cash flow from financing activities improved to CNY 255,142,167.21, compared to a net outflow of CNY 86,633,697.98 in the previous year[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,574,948,452.70, a 15.44% increase from ¥6,562,035,209.95 at the end of the previous year[4] - The total liabilities increased to CNY 3,003,912,688.12 from CNY 2,375,948,241.39, indicating a rise of about 26%[31] - The company's inventory reached CNY 981 million, up from CNY 757 million at the beginning of the year[26] - The total current assets amounted to CNY 3.995 billion, compared to CNY 3.211 billion at the beginning of the year[26] Operating Costs and Expenses - Operating costs rose to ¥736,658,489.58, reflecting a 127.65% increase from ¥323,599,198.21 in the previous year, primarily due to higher sales revenue[11] - R&D expenses increased by 59.75% to ¥104,914,096.80, driven by a rise in the number of R&D personnel and ongoing investments in technology platforms[11] - The company's tax expenses surged to ¥59,477,591.43, reflecting a 2,068.73% increase from ¥2,742,504.85, due to higher taxable income[11] - The total operating costs for the first quarter were CNY 1,008,533,596.22, compared to CNY 460,377,911.50 in the previous year, indicating an increase of about 118%[32] Shareholder Information - Shareholders' equity attributable to the parent company was ¥4,384,399,020.91, up 10.12% from ¥3,981,557,111.07 at the end of the last year[4] - The company has a total of 22,525 common shareholders as of the end of the reporting period, with the largest shareholder holding 14.51% of the shares[14] Business Growth - The core business segment, API CDMO, generated revenue of CNY 1.433 billion, up 173% year-on-year, driven by the gradual delivery of major orders[22] - The company signed contracts with 230 clients during the reporting period, with a total of 347 products signed, reflecting a 26% year-on-year growth[22] - The total number of employees increased to 4,158, a 10% growth compared to the end of 2021 and a 46% increase year-on-year[22]

Company Operations and Workforce - The company operates 14 facilities and has a global workforce of over 3,700 employees, including more than 1,200 in R&D[4][5]. - The company has delivered over 1,700 projects globally and introduced 212 new clients and projects in the reporting period[6]. - User data showed an increase in active clients by 30%, reaching a total of 1,500 clients by the end of 2021[36]. - The company has served over 290 API projects and successfully advanced 20 projects to the next development stage[6]. - The company has served over 600 clients and delivered nearly 1,800 projects, covering major disease treatment areas such as antiviral, oncology, and immunology[67]. - The company added 113 new clients in 2021, bringing the total number of service clients to 277, with the top ten clients accounting for 63% of total revenue[82]. Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year growth of 25%[36]. - The company's operating revenue for 2021 was ¥3,105,149,629.68, representing a 49.87% increase compared to ¥2,071,875,421.80 in 2020[42]. - The net profit attributable to shareholders was RMB 200 million, an increase of 15% compared to the previous year[36]. - The net profit attributable to shareholders for 2021 was ¥523,915,383.33, a 61.49% increase from ¥324,416,211.29 in 2020[42]. - The net profit after deducting non-recurring gains and losses was ¥502,713,329.09, up 74.42% from ¥288,226,952.19 in 2020[42]. - The company aims to achieve a revenue target of RMB 1.5 billion for 2022, reflecting a growth forecast of 25%[36]. - The gross margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[36]. - The company’s net profit attributable to shareholders was 524 million yuan, a year-on-year increase of 61%, with a net profit margin of 15.32%[80]. Research and Development - The company has invested RMB 300 million in R&D, focusing on gene and cell therapy technologies[36]. - R&D expenses increased by 67.15% to 264 million yuan, with a R&D expense ratio of 8.50%, reflecting a 52% growth in R&D personnel[81]. - The company operates eight R&D centers in China and the U.S., employing a total of 1,201 R&D personnel, with 1,098 in China and 103 in the U.S.[70]. - New product development includes a pipeline of 10 innovative drugs, with 3 expected to enter clinical trials in 2022[36]. - The company has established a digital laboratory system (E-Lab) aimed at enhancing research and development efficiency through digital transformation[110]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 20% increase in market share by 2023[36]. - The company plans to expand its market presence in the CDMO industry, which is characterized by low concentration and high specialization[51]. - The company is focused on becoming the most open, innovative, and reliable pharmaceutical service platform globally, providing comprehensive CDMO services[8]. - The company’s strategic new businesses, although still in the capability-building phase, have started generating revenue, contributing to future growth opportunities[80]. Compliance and Safety - The company has a commitment to EHS (Environment, Health, and Safety) as a core competitive advantage, with annual training for employees and continuous improvement in process technology[14]. - The company is committed to maintaining compliance with GMP standards across all manufacturing facilities[36]. - The company has established a robust EHS management system, which is crucial for sustainable development in the CDMO industry[73]. Investment and Acquisitions - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in biologics manufacturing[36]. - The company acquired 70% of Yuyang Pharmaceutical for CNY 171.5 million, which was completed on September 16, 2021, and included in the consolidated financial statements[123]. - The company invested a total of ¥1,011,815,424.69 during the reporting period, a 74.88% increase compared to the previous year[140]. Operational Efficiency - The company has automated approximately 75% of the operational units in its 109 workshop, enhancing operational efficiency and flexibility[110]. - The company’s production capacity grew by approximately 65% in 2021, reaching about 2,019 cubic meters[99]. - The company’s comprehensive capacity coverage rate improved to 72%, with production volume increasing by 25% year-on-year[106]. Challenges and Risks - New business segments have collectively reduced net profit by approximately 106 million RMB during the reporting period, indicating ongoing investment and development challenges[16]. - The company has faced foreign exchange losses of 39.77 million RMB in 2020, highlighting the impact of currency fluctuations on performance[15]. - The overall success rate of drug development has declined, with a rate of 9.8% in 2020, prompting pharmaceutical companies to increase their outsourcing of drug development to CDMO firms[56].

股票代码：300363 股票简称：博腾股份 公告编号：2021-115 号 重庆博腾制药科技股份有限公司 关于参加重庆辖区 2021 年投资者网上集体接待日活动 的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步做好投资者关系管理工作，增强与广大投资者的互动交流，重庆博 腾制药科技股份有限公司（以下简称"公司"）将于 2021 年 11 月 25 日（星期 四）参加由重庆上市公司协会与深圳市全景网络有限公司联合举办的"重庆辖区 2021 年投资者网上集体接待日"活动，现将有关事项通知如下： 一、活动内容 公司将就公司治理、经营状况、可持续发展等投资者所关心的问题，通过"全 景 路演天下"平台与投资者进行"一对多"形式的在线交流。 二、参加人员 公司副董事长、副总经理、董事会秘书陶荣先生，证券事务代表皮薇女士。 三、活动时间 2021 年 11 月 25 日（星期四）15:00-17:00。 四、投资者参加方式 投资者可在 2021 年 11 月 25 日（星期四）15:00-17:00 通过互联网直接登陆 http://rs.p5w.net/c/3 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥773,997,978.15, representing a 37.52% increase year-over-year[7] - Net profit attributable to shareholders was ¥146,131,880.12, up 35.23% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥151,559,752.54, reflecting a 49.64% increase year-over-year[7] - Operating revenue for the first nine months of 2021 reached CNY 2,029,816,801.54, an increase of 36.41% compared to CNY 1,488,074,665.79 in the same period of 2020[14] - For the first three quarters of 2021, the company achieved a revenue of 2.03 billion RMB, representing a year-on-year growth of 36.41%[28] - The net profit attributable to shareholders for the same period was 361 million RMB, a year-on-year increase of 50.92%[28] - The overall gross margin for the first three quarters was 43.71%, up 2.16 percentage points from the previous year, while the net profit margin was 17.03%, an increase of 1.02 percentage points[28] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,875,751,349.57, a 30.66% increase from the end of the previous year[7] - The total number of common shareholders at the end of the reporting period is 22,247[21] - The total liabilities increased significantly, with accounts payable rising by 56.03% to CNY 460,222,415.93 due to increased procurement[14] - The company’s total current liabilities increased to RMB 1,667,183,933.67 from RMB 984,022,123.94 at the end of 2020[59] - Total liabilities amounted to $1,103,697,701.72, a decrease from $1,150,455,806.91, reflecting a reduction of $46,758,105.19[82] Cash Flow - The company recorded a net cash flow from operating activities of ¥250,627,959.49, which is a decrease of 26.35% year-over-year[7] - The company reported a net cash inflow from operating activities of CNY 1,760,701,968.10, a 32.92% increase from CNY 1,324,629,405.66 in the previous year[17] - The net cash flow from operating activities was $250.63 million, a decrease of 26.4% compared to $340.28 million in the previous period[73] - Cash inflow from financing activities was $522.35 million, down from $1.16 billion in the previous period[73] - The net cash flow from financing activities was $253.37 million, compared to $82.80 million in the previous period, indicating a substantial increase[73] Research and Development - R&D expenses increased by 95.81% to CNY 223,621,085.82, driven by an increase in R&D personnel and expansion of laboratory facilities[14] - The company invested 224 million RMB in R&D, accounting for 11.02% of total revenue, a 95.81% increase year-on-year[37] - Research and development expenses surged to ¥223,621,085.82, a significant increase from ¥114,200,845.95 in the previous period[66] Shareholder Information - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.72% of shares, totaling 80,112,365 shares[21] - The second-largest shareholder, Ju Nianfeng, holds 10.82% of shares, totaling 58,890,521 shares, with 50,480,087 shares pledged[21] - The company plans to repurchase and cancel 18,000 restricted shares from a departing incentive object, pending completion of procedures[26] - The total number of shares held by Ju Nianfeng is 50,480,087, which are subject to executive lock-up[24] Acquisitions and Investments - The company completed the acquisition of 70% of Hubei Yuyang Pharmaceutical Co., Ltd. for RMB 171.5 million, which was officially registered on September 16, 2021, and is now included in the consolidated financial statements[53] - Fixed assets increased by 25.37% to CNY 1,709,187,056.99, primarily due to the acquisition of 70% equity in Hubei Yuyang Pharmaceutical Co., Ltd.[14] - The company recognized goodwill of CNY 278,520,496.76, reflecting the acquisition of 70% equity in Hubei Yuyang Pharmaceutical Co., Ltd.[14] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[3] - The raw material CDMO business generated a revenue of 1.398 billion RMB, accounting for 69% of total revenue, with a year-on-year growth of 40%[38] - The gene and cell therapy CDMO business signed new orders worth approximately 105.11 million RMB, serving 11 clients and managing 16 projects[52] - The formulation CDMO business secured new orders amounting to 32.16 million RMB, serving 12 clients and managing 13 projects[52] Employee Information - The company expanded its global team to 3,610 employees, an increase of 975 from the end of 2020[28]

Client and Project Engagement - The company has served over 500 global clients and delivered more than 1,700 projects, with over 260 API projects completed[14] - The company has 9 active clients and 10 active projects in the chemical formulation CDMO segment, and 12 clients with 14 projects in the gene and cell therapy CDMO segment[14] - User data indicates a 20% increase in the number of active clients in the biopharmaceutical sector[28] - The company has established business relationships with over 500 clients, including major global pharmaceutical companies, enhancing its competitive edge in the CDMO industry[87] Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 25%[28] - The company's revenue for the reporting period was ¥1,255,818,823.39, representing a 35.73% increase compared to ¥925,265,981.10 in the same period last year[37] - Net profit attributable to shareholders was ¥214,568,940.73, a 63.86% increase from ¥130,944,736.54 year-over-year[37] - The net profit after deducting non-recurring gains and losses was ¥201,282,796.53, reflecting a 69.99% increase compared to ¥118,406,579.45 in the previous year[37] - The company's total assets increased by 16.56% to ¥5,241,426,275.19 from ¥4,496,939,175.86 at the end of the previous year[37] - The company achieved a net profit of 300 million yuan in the same period, reflecting a growth of 20% compared to the previous year[127] Research and Development - The R&D expenditure for new drug development reached RMB 150 million, accounting for 12.5% of total revenue[28] - The company plans to launch three new innovative drugs by the end of 2022, targeting oncology and autoimmune diseases[28] - The company has initiated a strategic partnership with a leading technology firm to enhance its drug development processes[28] - The company has a comprehensive technology platform covering drug route design, crystallization, and biocatalysis among others[13] - The company has allocated 200 million yuan for R&D in 2021, which is a 40% increase from the previous year[128] Market Expansion and Strategy - The company is focused on expanding its services in various therapeutic areas including antiviral, oncology, and rare diseases[9] - The company is exploring potential acquisitions in Europe to enhance its market presence and capabilities[28] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[128] - Future guidance estimates a revenue growth of 15-20% for the second half of 2021[28] - The company aims to reduce production costs by 15% through the implementation of new technologies in manufacturing processes[128] Environmental Compliance and Sustainability - The company reported a wastewater pollutant discharge of less than 0.2 mg/L for chlorobenzene, which complies with the GB21904-2008 standard[125] - The company achieved a volatile organic compounds (VOCs) emission of 3.87 tons, significantly lower than the 66.738 tons limit set by the air pollution discharge standards[126] - The company has implemented measures to ensure that all emissions are below the specified limits, demonstrating a commitment to environmental compliance[125] - The company has invested in upgrading its wastewater treatment facilities to enhance compliance with environmental standards[126] - The company has established a comprehensive approach to pollution prevention and control, focusing on both wastewater and waste gas treatment processes[132] Corporate Governance and Shareholder Engagement - The company maintains good communication with investors through various online platforms and organizes performance briefings and investor open days[138] - The company ensures the protection of shareholder and creditor rights by adhering to legal requirements and providing convenient voting methods for shareholders[137] - The company reported a participation rate of 55.36% in the first extraordinary general meeting, indicating strong investor engagement[115] - The company’s governance and incentive plans are detailed in the corporate governance section of the report[175] Employee and Workforce Development - The company has a global employee count of 3,054 and a production capacity of over 900 m³ for API[12] - The total number of employees reached 3,054, an increase of 419 from the end of 2020, with R&D personnel growing from 714 to 909, representing 30% of the workforce[54] - The company launched a restricted stock incentive plan for 2021, marking the third consecutive year of such initiatives aimed at mid-to-senior management and key technical personnel[77] Risk Management - The company emphasizes risk management related to market demand fluctuations and new business investments[18] - The company faced risks related to the potential recall of innovative drugs and fluctuations in terminal market demand, which could significantly impact sales and performance[108] - The company is actively exploring new technologies and applications that could impact its business operations positively[112] Investment and Financial Strategy - The total investment amount during the reporting period was ¥230,608,556.72, representing an increase of 84.87% compared to the previous year's investment of ¥124,738,765.30[97] - The company has committed to invest ¥54,651.65 million in the "East Pharmaceuticals Azvudine and other 9 product construction projects" and ¥113,888.05 million in the "Biopharmaceutical CMO construction project"[102] - The company has established an asset investment decision committee to ensure prudent decision-making regarding new fixed asset investments[108] Community Engagement and Social Responsibility - The company donated 100,000 yuan to the Chongqing Charity Federation in July 2021 for poverty alleviation efforts in Wushan County[141] - The company has committed to social responsibility through various community support activities, including elderly care and environmental protection[141] - The company has actively participated in rural revitalization efforts in response to national strategic goals[141]

Financial Performance - The company's revenue for Q1 2021 was ¥542,859,651.10, representing a 38.99% increase compared to ¥390,571,812.66 in the same period last year[6] - Net profit attributable to shareholders was ¥88,091,336.52, an increase of 82.90% from ¥48,164,934.36 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥75,267,992.56, up 55.72% from ¥48,336,440.22 in the previous year[6] - The basic earnings per share increased to ¥0.16, a rise of 77.78% compared to ¥0.09 in the same period last year[6] - The overall gross margin improved to 40.39%, an increase of 2.45 percentage points compared to the same period last year, while the net margin rose to 16.15%, up 4.09 percentage points[25] - Net profit for Q1 2021 reached CNY 87,676,028.93, a significant increase of 86% compared to CNY 47,115,764.27 in the same period last year[72] - The company reported a basic and diluted earnings per share of CNY 0.16, compared to CNY 0.09 in Q1 2020[72] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,683,978,701.75, a 4.16% increase from ¥4,496,939,175.86 at the end of the previous year[6] - The net assets attributable to shareholders increased to ¥3,473,426,009.80, reflecting a 2.42% growth from ¥3,391,430,127.18 at the end of the previous year[6] - Total liabilities amounted to CNY 1,208,922,197.61, compared to CNY 1,103,697,701.72, reflecting an increase of 9.5%[63] - The total current liabilities increased to CNY 1,028,198,822.30 from CNY 984,022,123.94, an increase of 4.5%[63] Cash Flow - The net cash flow from operating activities was ¥35,593,516.02, a decrease of 64.62% compared to ¥100,608,444.60 in the same period last year[6] - The cash flow from operating activities showed improvement, with a net cash inflow of CNY 50,000,000 compared to a net outflow in the previous year[20] - The total cash and cash equivalents at the end of the period decreased to ¥990,206,419.62 from ¥1,165,567,157.85 year-over-year[78] - Cash paid to employees increased to ¥137,993,113.18, compared to ¥96,429,073.41 in the same quarter last year, reflecting a 43.3% increase[77] Investments and R&D - Research and development expenses surged by 98.07% to CNY 65,675,223.56, indicating a strong commitment to innovation and product development[20] - The company expanded its gene and cell therapy CDMO business, serving 7 clients and establishing a GMP production platform for various products[35] - The company has continued to advance its formulation CDMO business, achieving collaboration with 9 clients during the reporting period[38] - The company completed a financing round in April 2021, raising CNY 400 million to enhance its gene therapy business capabilities[35] Market and Business Strategy - The company plans to expand its market presence and enhance its product offerings through strategic partnerships and acquisitions in the coming quarters[20] - The company is focusing on transitioning from CMO to CDMO business models to optimize project investment[54] - Major risks include potential market demand fluctuations for innovative drugs, which could significantly affect sales and overall performance[40] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,137[9] - Shareholders with over 5% stakes have pledged significant shares, with the largest pledges being 45.47 million shares, representing 8.38% of total shares[44] - The company plans to reduce shares by up to 5,404,473 shares, representing 1% of the total share capital of 540,747,533 shares, starting from December 1, 2020[46] Other Notable Events - The company has initiated a new leasing standard, resulting in the recognition of lease liabilities amounting to CNY 124,091,256.10[19] - The company has liquidated and deregistered its subsidiary, Chongqing Dexin Pharmaceutical Technology Partnership, due to unmet fundraising expectations influenced by external macroeconomic conditions and the COVID-19 pandemic[46] - The company approved the 2021 Restricted Stock Incentive Plan, which aims to enhance sustainable development and protect shareholder interests[47]

Financial Performance - The company's operating revenue for 2020 was CNY 2,071,875,421.80, representing a 33.56% increase compared to CNY 1,551,298,762.27 in 2019[36]. - The net profit attributable to shareholders for 2020 was CNY 324,416,211.29, a significant increase of 74.84% from CNY 185,550,375.49 in 2019[36]. - The net profit after deducting non-recurring gains and losses was CNY 288,226,952.19, up 77.82% from CNY 162,088,354.80 in 2019[36]. - The company's cash flow from operating activities for 2020 was CNY 504,374,812.57, an increase of 43.54% compared to CNY 351,373,889.80 in 2019[36]. - The total assets at the end of 2020 were CNY 4,496,939,175.86, reflecting a 13.69% increase from CNY 3,955,481,924.55 at the end of 2019[36]. - The net assets attributable to shareholders at the end of 2020 were CNY 3,391,430,127.18, a 10.59% increase from CNY 3,066,684,114.86 at the end of 2019[36]. - The company reported a basic earnings per share of CNY 0.61 for 2020, which is a 74.29% increase from CNY 0.35 in 2019[36]. - The overall gross margin for the year was 41.68%, an increase of 3.84 percentage points compared to the previous year[54]. - The company achieved a total revenue of 2.072 billion yuan, representing a year-on-year growth of 33.56%, with all revenue coming from the API CDMO segment[53]. Client and Market Expansion - The company served over 1,400 clients globally and completed 10 innovative drug PV projects in 2020, with more than 500 active projects[13]. - The revenue concentration from the top ten clients decreased to 54% and from the top ten products to 31%, indicating improved business resilience[17]. - The company is expanding its global footprint with multiple development and production centers in China, Belgium, Switzerland, and the USA[10]. - The company has established strategic partnerships with major global pharmaceutical companies, including Johnson & Johnson, Pfizer, and Roche, enhancing its market position[44]. - The company has established business relationships with nearly 500 clients globally, including 16 of the top 20 pharmaceutical companies, providing contract custom R&D and production services for approximately 1,400 projects[45]. Investment and Capital Expenditure - The company plans to invest 278 million CNY in the construction of a formulation factory in Chongqing, enhancing its CDMO capabilities[89]. - The company has committed a total investment of 168,539.7 million CNY, with 146,202.76 million CNY already utilized, representing an investment progress of approximately 86.8%[125]. - The company raised a total of RMB 146,202.76 million in funds, with RMB 8,095.77 million directly invested in fundraising projects in 2020[122]. - The company utilized RMB 101,640.85 million for repaying bank loans and supplementing working capital, with RMB 98,877.05 million coming from the net amount of raised funds[122]. Research and Development - R&D expenses amounted to 158 million CNY, representing 7.62% of total revenue, an increase of 28.79% compared to the previous year[81]. - The number of R&D personnel increased to 599 in 2020, up from 393 in 2019, representing a growth rate of 52.5%[111]. - The company is actively involved in the research and development of new drugs, enhancing its competitive edge in the pharmaceutical sector[119]. - The company expanded its enzyme library by 183 enzymes and completed 54 screening projects, with 8 entering the process development or product delivery stage[83]. Environmental, Health, and Safety (EHS) - The company has established a comprehensive EHS (Environment, Health, and Safety) system, which has become a core competitive advantage, with annual EHS training for employees[20]. - The company emphasizes compliance and delivery records as core competitive advantages, which are crucial for maintaining long-term client relationships[58]. - The company reported a total wastewater discharge of 41.25 tons for chemical oxygen demand, well below the regulatory limit of 88.969 tons[193]. - The company strictly adheres to environmental protection laws, investing in pollution control and promoting sustainable development[192]. Dividend and Shareholder Returns - The profit distribution plan approved by the board proposes a cash dividend of RMB 1.21 per 10 shares (tax included) to all shareholders, based on a total of 540,447,320 shares[23]. - The cash dividend accounted for 20.16% of the total distributable profit of RMB 324,416,211.29[151]. - The company has maintained a consistent cash dividend distribution policy over the years, with a previous year's distribution of RMB 55,768,182.08, which was 30.06% of the net profit[151]. Strategic Shifts and Business Model Transformation - The company aims to transform its business model from CMO to CDMO, focusing on marketing transformation, product upgrades, and process development[125]. - The company is transitioning from CMO to CDMO, focusing on small and medium-sized clients and the North American market, driven by the increasing demand for high-value-added process development[133]. - The implementation of the MAH system in China is a significant policy support for the rapid development of the CDMO industry, facilitating the transformation of the pharmaceutical sector[135]. Challenges and Risks - The company faced foreign exchange risks, with exchange gains and losses of 427.28 million RMB, 291.06 million RMB, and -3,976.78 million RMB from 2018 to 2020[21]. - The company is actively addressing the challenges posed by raw material price increases and exchange rate fluctuations, which have affected accounts receivable and project delivery cycles[144]. - The company has faced uncertainties and risks in its core product performance, prompting a strategic shift in resource allocation[125]. Employee and Social Responsibility - The company emphasizes employee welfare, providing various training programs and fostering a harmonious labor relationship[191]. - The company actively participates in social welfare activities, including donations for pandemic prevention efforts[192]. - The company has established a union to enhance employee participation in management and promote a stable labor relationship[191].

股票代码：300363 股票简称：博腾股份 公告编号：2020-088 号 重庆博腾制药科技股份有限公司 关于参加 2020 年重庆辖区上市公司投资者网上集体接待日 主题活动的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）将于 2020 年 11 月 26 日（星期四）参加由重庆上市公司协会与深圳市全景网络有限公司联合举办 的"2020 年重庆辖区上市公司投资者网上集体接待日"活动，现将有关事项通 知如下： 一、活动内容 公司将通过网络在线交流形式，就公司治理、经营状况、可持续发展、维护 投资者权益创新举措等投资者所关心的问题，通过"全景 路演天下"平台与 投资者进行"一对多"形式的在线交流。 二、参加人员 副董事长、副总经理、董事会秘书陶荣先生，副总经理、财务负责人孙敏先 生，证券事务代表皮薇女士。 三、活动时间 2020 年 11 月 26 日（星期四）15:00-16:30。 四、投资者参加方式 投资者可在 2020 年 11 月 26 日（星期四）15:00-16:30 通过互联网直接登陆 http ...

Financial Performance - Operating revenue for the period was ¥562,808,684.69, representing a year-on-year growth of 23.16%[8] - Net profit attributable to shareholders was ¥108,060,449.39, up 53.48% from the same period last year[8] - Basic earnings per share rose to ¥0.20, reflecting an increase of 53.85% year-on-year[8] - The company's operating revenue for the current period reached ¥562,808,684.69, representing an increase of 23.1% compared to ¥456,970,394.86 in the previous period[80] - The net profit for the current period was ¥107,861,468.71, a significant increase of 53.1% from ¥70,404,835.21 in the same period last year[84] - Total operating revenue for the current period reached ¥1,488,074,665.79, a significant increase of 37.6% compared to ¥1,081,495,032.06 in the previous period[91] - Net profit for the current period was ¥238,203,864.50, representing a 75.5% increase from ¥135,716,174.08 in the same period last year[93] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,408,802,389.44, an increase of 11.46% compared to the end of the previous year[8] - The total liabilities increased to ¥1,176,669,786.83, up from ¥969,674,910.39, reflecting a growth of approximately 21.4%[76] - The total assets amounted to ¥4,310,001,769.38, compared to ¥3,923,273,681.17, indicating a rise of about 9.9%[76] - The company's total liabilities included long-term borrowings of ¥241,740,072.00[118] - The total liabilities were reported at ¥891,163,683.95, with current liabilities amounting to ¥647,192,709.16[118] Cash Flow - Net cash flow from operating activities increased significantly by 213.17% to ¥182,168,256.47[8] - Cash inflow from operating activities totaled CNY 1,437,319,735.95, an increase of 14.9% compared to CNY 1,250,877,673.28 in the previous period[102] - Cash inflow from financing activities amounted to CNY 1,163,362,018.47, significantly higher than CNY 658,299,411.78 in the prior period, marking an increase of 76.5%[105] - The company reported a net increase in cash and cash equivalents of CNY 166,366,249.02, contrasting with a decrease of CNY -220,111,038.00 in the previous period[105] Shareholder Information - The top ten shareholders held a combined 66.07% of the company's shares, with the largest shareholder owning 15.76%[11] - The company has a total of 18,004 common shareholders at the end of the reporting period[11] - Major shareholders have pledged shares, with the largest pledges being 51.75 million shares (76.89% of their holdings) by the controlling shareholder[48] Research and Development - The company's R&D investment for the first nine months of 2020 amounted to 114 million yuan, accounting for 7.67% of revenue, an increase of 27.21% year-on-year[44] - Research and development expenses increased to ¥48,979,068.15, up 79.4% from ¥27,333,463.97 in the prior period, indicating a strong focus on innovation[80] - The R&D team has expanded to 695 members, representing 27% of total employees, with 91 in the overseas team and 497 in the domestic team[44] Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development[9] - The company received 60.07 million CNY in tax refunds, a 65.62% increase due to increased exports and changes in tax refund policies[27] - The company invested 266.6 million CNY in fixed assets, a significant increase of 182.46% year-on-year, driven by new project investments[27] Operational Efficiency - The overall gross margin improved to 41.55%, up 4.02 percentage points from the previous year, while the net margin reached 16.01%, an increase of 3.46 percentage points[32] - The company reported that the average value and gross margin of single orders in CRO projects were discussed, indicating a focus on operational efficiency and profitability[57] Financial Management - The company experienced a financial expense of ¥19,346,856.45, compared to a financial income of ¥4,847,724.60 in the previous period, indicating a shift in financial management[80] - The tax expenses for the current period were ¥17,687,484.68, up from ¥13,820,932.37 in the previous period, reflecting increased profitability[84]

Company Overview - The company has over 420 active projects and serves more than 430 global clients, with a cumulative total of over 1,200 successful projects[8]. - The company has a total of 81 laboratories globally, with 39 laboratories currently under construction (36 in China and 3 in the USA)[8]. - The company employs 2,373 people, with 475 in R&D, accounting for 20% of the workforce[7]. - The company has established business relationships with over 430 global clients, including 16 of the top 20 pharmaceutical companies[45]. - The company has expanded its global team from over 2,000 to over 2,370 employees to support ongoing business growth[74]. Financial Performance - The company reported a revenue of RMB 1.2 billion for the first half of 2020, representing a year-on-year increase of 15%[28]. - The company's operating revenue for the reporting period reached ¥925,265,981.10, representing a 48.16% increase compared to ¥624,524,637.20 in the same period last year[37]. - The net profit attributable to shareholders was ¥130,944,736.54, a 100.49% increase from ¥65,311,176.20 year-on-year[37]. - The company reported a net profit of RMB 300 million for the first half of 2020, up 10% year-on-year[28]. - The net cash flow from operating activities was ¥158,107,962.11, reflecting a 44.94% increase compared to ¥109,087,606.08 in the same period last year[37]. - The overall gross profit margin for the reporting period was 38.60%, an increase of 1.45 percentage points year-on-year[75]. - The company aims for a revenue growth target of 20% for the full year 2020[28]. Research and Development - The R&D expenditure for the first half of 2020 was RMB 150 million, accounting for 12.5% of total revenue[28]. - The company has a strong R&D capability with 475 personnel across four research centers in China and the US, focusing on innovative and efficient solutions[68]. - The company has established a comprehensive end-to-end R&D and production service model, catering to various stages of drug development from preclinical to commercialization[55]. - The company is focusing on developing its new strategic businesses, including formulation CDMO and biological CDMO services, which are currently in the early stages of cultivation[48]. - The company completed one innovative drug process validation project and is currently working on two additional projects[89]. Business Strategy and Development - The company aims to become the most open, innovative, and reliable pharmaceutical service platform globally[4]. - The company is exploring potential acquisitions in the biopharmaceutical sector to enhance its product portfolio[28]. - The company aims to provide end-to-end pharmaceutical services, leveraging its extensive experience in the CDMO sector to support global pharmaceutical companies[44]. - The company has established a new research facility in Belgium to support its European market expansion[28]. - The company has initiated two new business segments, formulation CDMO and biological CDMO, which reduced net profit by approximately 14.90 million RMB in the first half of 2020[133]. Market and Client Engagement - User data indicates a 25% increase in the number of active clients in the CDMO segment[28]. - The company received 467 new inquiries in the first half of 2020, with 56 product orders confirmed during the reporting period[87]. - The company has served over 400 clients, including major global pharmaceutical companies, establishing a broad cooperative foundation for future business development[70]. - The company’s top ten customers' revenue contribution decreased to 58% and 57% in the last year and the current period, respectively, improving customer concentration[129]. Environmental and Safety Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[167]. - The company reported a total of 13.6354 tons of volatile organic compounds in direct emissions, which is within the regulatory limits[170]. - The company has implemented trade financing and guarantee business within the approved comprehensive credit limit[164]. - The company’s production bases comply with national environmental protection regulations and standards[186]. - The company’s environmental management system integrates environmental protection into all operational aspects, promoting energy conservation and emission reduction among employees[186]. Talent and Human Resources - A total of 30 senior managers were recruited in the first half of 2020, enhancing the company's talent pool[99]. - The company launched a restricted stock incentive plan in June 2020 to attract and retain talent[99]. - The company granted 175,000 restricted stocks to 2 incentive objects on May 14, 2020[146]. - The company plans to grant 1,033,000 restricted stocks to 24 incentive objects on June 29, 2020[150]. Risks and Challenges - The company faces various risks, including market demand fluctuations and new business investment risks[16]. - The company has implemented measures to monitor and manage foreign exchange risks due to its reliance on exports priced in foreign currencies[133]. - The company aims to reduce customer and product concentration to enhance its resilience against market fluctuations[129]. Shareholder Information - The controlling shareholders have pledged a total of 64,380,772 shares (95.65%), 49,313,980 shares (98.00%), and 55,451,997 shares (99.62%) respectively, which account for 11.86%, 9.09%, and 10.22% of the total share capital[189]. - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 15.76% of the shares, totaling 85,552,865 shares[199]. - The company has 19,377 shareholders holding more than 5% of the ordinary shares as of the end of the reporting period[199].